PPIIPP--DDPerformance Improvement

Program in Surgical Pathology

PARTICIPANT SUMMARY

© 2009 College of American Pathologists. The College does not permit reproduction of any substantial portion of the material in this Report without its written authorization. The College hereby authorizes participants in the program to use the material in this Report solely for educational purposes within their own institutions. The College prohibits use of the material in the Report - and any unauthorized use of the College’s name or logo - in connection with promotional efforts by marketers of laboratory equipment, reagents, materials, or services. Data from this program do not necessarily indicate the superiority or inferiority of instruments, reagents, or other materials used by participating laboratories. Use of these data to suggest such superiority or inferiority may be deceptive and misleading. The College will take all steps open to it under the law to prevent unauthorized reproduction of substantial portions of the material in this Report, deceptive use of any such material, and any unauthorized use of the College’s name or logo in connection with promotional efforts by marketers of laboratory equipment, reagents, materials, or services.

2009 PIP-D

PARTICIPANT SUMMARY Program Update This report summarizes the diagnostic responses for set D of the 2009 Performance

Improvement Program in Surgical Pathology (PIP). A tabulation of the responses to the supplementary questions is not included since these are intended for educational purposes only.

SURGICAL PATHOLOGY COMMITTEE

Mary Beth Beasley, MD, Chair Arthur R. Cohen, MD, Vice Chair

Hagen J. Blaszyk, MD Alyssa M. Krasinskas, MD Philip A. Branton, MD Daniel J. Luthringer, MD Benjamin C. Calhoun, MD, PhD Samuel McCash, MD Liang Cheng, MD Marisa Rose Nucci, MD Byron E. Crawford, MD Vijaya B. Reddy, MD Michael T. Deavers, MD Mary S. Richardson, MD, DDS Rajan Dewar, MD, PhD Gene P. Siegal, MD, PhD Megan K. Dishop, MD Saul Suster, MD Sanjay Kakar, MD

1

2

Diagnosis (2651) Cortical tuber associated with tuberous sclerosis Participants Code Diagnosis No. % 2650

(malformation of cortical development) Cortical dysplasia 473

9.1

2651 Cortical tuber associated with tuberous sclerosis 4593 88.4 2652 Diffuse fibrillary astrocytoma 62 1.2 1512 Ganglioglioma 29 0.6 2653 Gemistocytic astrocytoma 21 0.4 2654 Subependymal giant cell astrocytoma 14 0.3 Technical Quality of Slide

Participants Rating Slide Evaluation No. % 001 Excellent 1862 39.4 002 1470 31.2 003 Satisfactory 1265 26.8 004 106 2.3

Cas

e #

2009

-31

005 Unsatisfactory 13 0.3

Diagnosis (2229) Pseudomembranous colitis secondary to Clostridium difficile infection Participants Code Diagnosis No. % 2655

Enterohemorrhagic colitis secondary to E. coli infection

29

0.6

2227 Ischemic colitis 22 0.4 2656 Mycophenolate mofetil associated colitis 51 1.0 2229

Pseudomembranous colitis secondary to Clostridium difficile infection

5109

97.9

2230 Ulcerative colitis 4 0.1 Technical Quality of Slide

Participants Rating Slide Evaluation No. % 001 Excellent 1703 36.5 002 1461 31.4 003 Satisfactory 1310 28.2 004 167 3.6

Cas

e #

2009

-32

005 Unsatisfactory 12 0.3

3

Diagnosis (2314) Squamous cell carcinoma Participants Code Diagnosis No. % 2657 Adenocarcinoma, solid type with mucin production 21 0.4 1655 Adenosquamous carcinoma 111 2.1 2192 Basaloid carcinoma 4 0.1 2658 Large cell carcinoma 148 2.8 2314 Squamous cell carcinoma 4931 94.6 Technical Quality of Slide

Participants Rating Slide Evaluation No. % 001 Excellent 2189 46.6 002 1309 27.9 003 Satisfactory 1090 23.3 004 88

Cas

e #

2009

-33

005 Unsatisfactory 121.90.3

Diagnosis (1265) Myeloid sarcoma Participants Code Diagnosis No. % 2081 Adult granulosa cell tumor 47 0.9 2453 Burkitt lymphoma 75 1.4 2398 Large cell lymphoma 164 3.2 2476 Metastatic carcinoma 7 0.1 1265 Myeloid sarcoma 4880 93.7 2659 Undifferentiated carcinoma of the ovary 34 0.7 Technical Quality of Slide

Participants Rating Slide Evaluation No. % 001 Excellent 1949 42.1 002 1416 30.6 003 Satisfactory 1149 24.9 004 102

Cas

e #

2009

-34

005 Unsatisfactory 82.20.2

4

Diagnosis (2663) Undifferentiated (anaplastic) thyroid carcinoma Participants Code Diagnosis No. % 2660 Anaplastic medullary carcinoma 141 2.7 2398 Large cell lymphoma 5 0.1 2661 Spindle cell sarcoma 5 0.1 2662 Spindled melanoma 5 0.1 2663 Undifferentiated (anaplastic) thyroid carcinoma 5054 97.0 Technical Quality of Slide

Participants Rating Slide Evaluation No. % 001 Excellent 1846 39.3 002 1444 30.9 003 Satisfactory 1247 26.7 004 116

Cas

e #

2009

-35

005 Unsatisfactory 262.50.6

Diagnosis (2467) Yolk sac tumor Participants Code Diagnosis No. % 2216 Clear cell carcinoma 9 0.2 2461 Dysgerminoma 20 0.4 1994 Embryonal carcinoma 23 0.4 1907 Endometrioid adenocarcinoma 4 0.1 2467 Yolk sac tumor 5163 98.9 Technical Quality of Slide

Participants Rating Slide Evaluation No. % 001 Excellent 2119 45.5 002 1342 28.9 003 Satisfactory 1103 23.8 004 72

Cas

e #

2009

-36

005 Unsatisfactory 91.60.2

5

Diagnosis (2664) Complete hydatidiform mole Participants Code Diagnosis No. % 1060 Choriocarcinoma 21 0.4 2664 Complete hydatidiform mole 4790 91.8 1413 Hydropic abortus 24 0.5 2524 Partial hydatidiform mole 383 7.3 Technical Quality of Slide

Participants Rating Slide Evaluation No. % 001 Excellent 2125 45.7 002 1332 28.7 003 Satisfactory 1103 23.8 004 74

Cas

e #

2009

-37

005 Unsatisfactory 81.60.2

Diagnosis (2665) Schwannoma with degenerative changes Participants Code Diagnosis No. % 1645 Desmoid tumor 8 0.2 1901 Gastrointestinal stromal tumor 10 0.2 2389 Leiomyosarcoma 19 0.4 1058 Myxofibrosarcoma 267 5.1 1700 Myxoid liposarcoma 450 8.6 2665 Schwannoma with degenerative changes 4455 85.5 Technical Quality of Slide

Participants Rating Slide Evaluation No. % 001 Excellent 1732 37.4 002 1480 32.0 003 Satisfactory 1256 27.2 004 134 2.9

Cas

e #

2009

-38

005 Unsatisfactory 24 0.5

6

Diagnosis (2667) Non-invasive papillary urothelial carcinoma Participants Code Diagnosis No. % 2666 Adenocarcinoma of the urinary tract 4 0.1 2667 Non-invasive papillary urothelial carcinoma 5102 98.0 1084 Papillary renal cell carcinoma 40 0.8 2561

potential (PUNLMP) Papillary urothelial neoplasm of low malignant 58 1.1

1517 Villous adenoma 0 0.0 Technical Quality of Slide

Participants Rating Slide Evaluation No. % 001 Excellent 2165 46.7 002 1294 27.9 003 Satisfactory 1094 23.6 004 76

Cas

e #

2009

-39

005 Unsatisfactory 101.60.2

Diagnosis (2485) Hepatocellular carcinoma Participants Code Diagnosis No. % 2387 Angiomyolipoma 3 0.1 2484 Focal nodular hyperplasia 49 0.9 2485 Hepatocellular carcinoma 5138 98.9 2465 Metastatic renal cell carcinoma 6 0.1 2668 Neuroendocrine tumor 0 0.0 Technical Quality of Slide

Participants Rating Slide Evaluation No. % 001 Excellent 2037 44.3 002 1367 29.7 003 Satisfactory 1094 23.8 004 84

Cas

e #

2009

-40

005 Unsatisfactory 161.80.4

332255 WWaauukkeeggaann RRooaaddNNoorrtthhffiieelldd,, IILL 6600009933--22775500

880000--332233--44004400 oorr884477--883322--77000000 ooppttiioonn 11